Departments of Internal Medicine and daggerPathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
J Thorac Oncol. 2010 Mar;5(3):320-5. doi: 10.1097/JTO.0b013e3181ce684f.
We analyzed the significance of class III beta-tubulin (TUBB3) expression in curatively resected non-small cell lung cancer as a prognostic marker along with previously reported excision repair cross complementation group 1 (ERCC1).
One hundred and thirty-six consecutive patients were included in this retrospective study. Patients who received adjuvant chemotherapy were excluded. We used immunohistochemistry to evaluate TUBB3 and ERCC1 expression on tissue microarray in duplicate. Semiquantitative H score was used for the scoring of tumor staining.
Sixty percent of patients had stage I disease, 17% stage II, 18% stage IIIA, and 5% stage IIIB. TUBB3 H score showed bimodal distribution with the minimum at the value of 4, which was used as a cutoff value for determination of TUBB3 positivity. TUBB3 was expressed in 60 patients (44%). Patients with a positive TUBB3 expression survived shorter than did the patients with a negative expression (5-year overall survival [OS] rate was 40% versus 61%; p = 0.005/5-year disease-free survival rate was 34% versus 55%; p = 0.024). ERCC1 expression showed tendency for prolonged OS without reaching statistical significance. A multivariate analysis that incorporated covariates including TUBB3 expression, age, stage, EGFR mutation status, histology, and ERCC1 expression showed that TUBB3 was an independent unfavorable prognostic factor for OS (hazard ratio 2.083; p = 0.008) and relapse free survival (hazard ratio 1.978; p = 0.020).
TUBB3 expression is an independent unfavorable prognostic marker in patients with curatively resected non-small cell lung cancer who did not receive adjuvant chemotherapy.
我们分析了 III 类β-微管蛋白（TUBB3）表达在可治愈性切除的非小细胞肺癌中的意义，将其作为一种预后标志物，同时分析了之前报道的切除修复交叉互补组 1（ERCC1）。
本回顾性研究纳入了 136 例连续患者。排除接受辅助化疗的患者。我们使用免疫组织化学在组织微阵列上重复评估 TUBB3 和 ERCC1 的表达。使用半定量 H 评分对肿瘤染色进行评分。
60%的患者为 I 期疾病，17%为 II 期，18%为 IIIA 期，5%为 IIIB 期。TUBB3 H 评分呈双峰分布，最小值为 4，将其用作确定 TUBB3 阳性的截止值。60 例患者（44%）表达 TUBB3。TUBB3 阳性表达的患者比 TUBB3 阴性表达的患者存活时间更短（5 年总生存率[OS]率为 40%对 61%；p=0.005/5 年无病生存率为 34%对 55%；p=0.024）。ERCC1 表达有延长 OS 的趋势，但未达到统计学意义。一项纳入 TUBB3 表达、年龄、分期、EGFR 突变状态、组织学和 ERCC1 表达等协变量的多变量分析表明，TUBB3 是 OS（风险比 2.083；p=0.008）和无复发生存率（风险比 1.978；p=0.020）的独立不良预后因素。
在未接受辅助化疗的可治愈性切除的非小细胞肺癌患者中，TUBB3 表达是独立的不良预后标志物。
